Molecular Advances in Artificial Reproduction and Female Health: From Molecular Diagnosis to the Treatment of Gynecological Diseases

Dear Colleagues,

As molecular and genetic technologies will form the basis for all our diagnostic and therapeutic options and shape therapeutical possibilities, including surgical therapeutic strategies for human reproduction, cancer treatment and gynecologic strategies, I am happy to invite you to participate in the publication of this Special Issue with an original paper, a case study or review.

Molecular diagnostic technologies can be divided into three techniques: polymerase chain reaction (PCR), in situ hybridization (ISH)/flow cytometry or fluorescent in situ hybridization (FISH) and next-generation sequencing (NGS). These have undergone a period of rapid development and growth over the last decades. Semi-quantitative tests have been replaced by precision medicine. The implementation of new high-complexity tests and their integration into the clinical molecular diagnostics laboratory has been a critical advancement to the goal of achieving precision medicine.

A strong program of quality control and quality assurance is necessary for the detection of problems, to monitor errors and implement methods to assure this quality.

My expertise partly relates to artificial reproductive technologies (ART) such as measuring sperm DNA fragmentation much more precisely employing the SCSA test, in comparison to earlier test methods. The sperm chromatin structure assay (SCSA) is a flow cytometric test that measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ. We partly apply these techniques in endocrinology, endometriosis, measuring hormones and preimplantation factors in embryo cultures, as well as the frame of gynecological endoscopic or micro invasive surgery (MIS), including targeted medical applications.

Prof. Dr. Liselotte Mettler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gynecological diseases
• molecular diagnostic technologies
• reproductive medicine
• artificial reproduction
• gynecological endocrinology
• adnexal tumors
• genital and breast cancer
• urogynecology
• uterine fibroids